Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Christoph

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesotheliomaDaniel C Christoph, Bernadette Reyna Asuncion, Celine Mascaux, et al.
Journal of Thoracic Disease|August 18, 2020
First-line treatment selection with organoids of an <i>EGFR</i>m + <i>TP53</i>m stage IA1 patient with early metastatic recurrence after radical surgery and follow-upZiqi Jia, Yanyu Wang, Lei Cao, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerMarcel Wiesweg, Wilfried E E Eberhardt, Henning Reis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialA Molassiotis, K Jordan, M Karthaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel Neal, Nick Pavlakis, Sang-We Kim, et al.
Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 17, 2012
Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesotheliomaDaniel C Christoph, Bernadette Reyna Asuncion, Celine Mascaux, et al.
Journal of Thoracic Disease|August 18, 2020
First-line treatment selection with organoids of an <i>EGFR</i>m + <i>TP53</i>m stage IA1 patient with early metastatic recurrence after radical surgery and follow-upZiqi Jia, Yanyu Wang, Lei Cao, et al.
Clinical Lung Cancer|June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet StudyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2016
High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung CancerMarcel Wiesweg, Wilfried E E Eberhardt, Henning Reis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trialA Molassiotis, K Jordan, M Karthaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2024
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and ChemotherapyJoel Neal, Nick Pavlakis, Sang-We Kim, et al.
Clinical and Translational Radiation Oncology|March 11, 2026
Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapyAndrea R Filippi, Jair Bar, Daniel C Christoph, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R StudyNicolas Girard, Jair Bar, Pilar Garrido, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Pageof 11